Genetic polymorphisms of the XXXX @entity71175 gene in @entity14 and its association with clinical outcome.

@entity1 @entity5 @entity22421 @entity71175 @entity4538 @entity14 @entity4334 @entity3689
UNASSIGNED: @entity4538 ) has been increasingly detected in @entity14 ( @entity14 ), and genetic polymorphisms in HCMV affect its pathogenesis. This study aimed to investigate HCMV genetic polymorphisms in @entity14 and its correlation with the clinical outcomes. We performed PCR and sequencing of a viral immunomodulatory gene, @entity71175 , in clinical isolates and @entity14 specimens. The @entity4334 and @entity3689 sequences were aligned, and a phylogenetic tree was constructed. The clinical, pathological, and survival data were compared among @entity5 with different @entity71175 genotypes. HCMV was detected in 49 (47.8%) of the @entity5 specimens. Genotype A predominated in 43 samples (22/43; 51.2%) with successful sequencing, followed by genotype B (13/43; 30.2%) and genotype C (8/43; 18.6%). The genotypic distribution was similar to that of the clinical isolates and those reported in other Asian populations. The @entity3689 sequence of genotype B was the most conserved. For stage II and III @entity14 @entity1 with @entity5 , disease-free survival (DFS) varied amongst the 3 major genotypes (p = 0.0046). The presence of genotype @entity22421 in the @entity5 was associated with a shorter DFS and independently predicted @entity5 recurrence in a multivariate Cox proportional hazards model (hazard ratio, 5.79; 95% confidence interval, 1.30-25.81; p = 0.021). By reverse-transcription PCR, @entity5 samples with genotype B viruses had the highest rate of @entity71175 expression. Our results suggest that genetic polymorphisms of HCMV @entity71175 were associated with clinical outcome in @entity14 and that HCMV may plays an immunomodulatory role in the @entity5 microenvironment of @entity14 .
